ARDUINI, Arduino
 Distribuzione geografica
Continente #
NA - Nord America 846
EU - Europa 740
AS - Asia 447
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 2.037
Nazione #
US - Stati Uniti d'America 840
CN - Cina 190
UA - Ucraina 139
IE - Irlanda 117
SE - Svezia 114
IT - Italia 103
TR - Turchia 103
SG - Singapore 91
FR - Francia 77
GB - Regno Unito 77
DE - Germania 51
IN - India 47
FI - Finlandia 31
RU - Federazione Russa 15
VN - Vietnam 11
CA - Canada 4
NL - Olanda 4
BE - Belgio 3
CZ - Repubblica Ceca 3
GR - Grecia 3
UZ - Uzbekistan 2
AT - Austria 1
BR - Brasile 1
CH - Svizzera 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
KE - Kenya 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PL - Polonia 1
Totale 2.037
Città #
Chandler 177
Jacksonville 151
Dublin 117
Singapore 83
Southend 68
Izmir 67
Princeton 61
Ashburn 48
Nanjing 48
Beijing 45
New York 40
Wilmington 32
Cambridge 26
Chieti 25
Dearborn 22
Nanchang 21
Altamura 16
Boardman 16
Santa Clara 15
Ann Arbor 14
Los Angeles 13
Dong Ket 11
Woodbridge 11
Shenyang 9
Vittuone 9
Washington 9
Helsinki 8
Jinan 7
Hebei 6
Ningbo 6
Tianjin 6
Jiaxing 5
Kunming 5
Bangalore 4
Falls Church 4
Hefei 4
Norwalk 4
Ottawa 4
Brno 3
Brussels 3
Buccinasco 3
Changsha 3
Hangzhou 3
Houston 3
Leawood 3
Pescara 3
Augusta 2
Düsseldorf 2
Fino Mornasco 2
Fuzhou 2
Grevenbroich 2
Guangzhou 2
Kocaeli 2
Munich 2
Nuremberg 2
Padova 2
Perugia 2
Romola 2
San Mateo 2
Shanghai 2
Tashkent 2
Zhengzhou 2
Adliswil 1
Auckland 1
Berlin 1
Cedar Knolls 1
Centobuchi 1
Clearwater 1
Grafing 1
Guarulhos 1
Guiyang 1
Haikou 1
Kraków 1
Lanzhou 1
London 1
Marano di Napoli 1
Mexico City 1
Milan 1
Moscow 1
Nairobi 1
Naples 1
Orange 1
Orlando 1
Ospitaletto 1
Pakistan 1
Panama City 1
Pasadena 1
Porto Sant'elpidio 1
Putian 1
Qingdao 1
Redmond 1
Rotterdam 1
Seattle 1
Simi Valley 1
Taizhou 1
Tappahannock 1
Tel Aviv 1
Wenzhou 1
Totale 1.309
Nome #
Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells 121
Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. 119
L-carnitine inhibits a subset of platelet activation responses in chronic uraemia 101
null 96
Vitamin E induction of experimental allergic encephalomyelitis in the Lewis rat. 91
Carnitine palmitoyltransferase and acyl-coA binding protein: two more players in the membrane phospholipid fatty acid turnover of human red cells? 87
In vitro microbiology studies on a new peritoneal dialysis connector 87
L-Carnitine is an osmotic agent suitable for peritoneal dialysis 85
Carnitine in metabolic disease: potential for pharmacological intervention 84
Defining the potential antidepressant mode of action of acetyl-l-carnitine. 84
L-carnitine in uremic anemia 83
Change in plasma amino acid concentrations during breath-hold diving at high altitude. 82
Current opinion on usage of L-carnitine in end-stage renal disease patients on peritoneal dialysis 80
Carnitine palmitoyltransferase as a potential target for treating diabetes: is inhibition or activation preferable? 79
null 79
Effect of ischemia and reperfusion on antioxidant enzymes and mitochondrial inner membrane proteins in perfused rat heart. 78
Effects of L-carnitine administration on erythrocyte survival in haemodialysis patients 73
Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine 72
Hypercoagulability in uraemia: role of increased surface exposure of phosphatidylserine on erythrocytes 65
Cellular properties of human erythrocytes preserved in saline-adenine-glucose-mannitol in the presence of L-carnitine 64
Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits) 64
L-carnitine may decrease platelet activation response with phosphatidylserine exposure in chronic uraemia 61
The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis 58
La carnitina come agente osmo-metabolico nelle soluzioni di dialisi peritoneale 56
null 55
Utilità di uno screening urinario in età scolastica 53
Nuova proposta di sostituire il glucosio con la carnitina nelle soluzioni di dialisi peritoneale 51
How to improve the biocompatibility of peritoneal dialysis solutions (without Jeopardizing the patient’s health) 38
Coupling Osmotic Efficacy with Biocompatibility in Peritoneal Dialysis: A Stiff Challenge 29
Alterazioni eritrocitarie e loro possibile ruolo nelle complicanze cardiovascolari dell’uremia 17
Erythrocyte alterations and increased cardiovascular risk in chronic renal failure 15
Toward personalized haemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fungerprint 11
Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis 1
Totale 2.219
Categoria #
all - tutte 9.015
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.015


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020208 0 0 0 0 0 0 45 31 20 70 35 7
2020/2021234 29 2 32 8 19 37 2 12 38 27 11 17
2021/2022156 11 4 6 37 9 3 7 7 17 6 8 41
2022/2023450 43 63 22 50 49 88 23 21 68 2 14 7
2023/2024237 13 5 17 5 17 116 30 1 1 9 2 21
2024/2025200 18 64 56 27 13 11 11 0 0 0 0 0
Totale 2.219